SCHEMBL7059153

SCHEMBL7059153

O=C(O)[C@H](NS(=O)(=O)Cc1ccc2sccc2c1)c1ccc(O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.38
ADRB3 P13945 1/20 0.36
CTNNB1 P35222 1/20 0.35
WNT3A P56704 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
YARS1 P54577 1/20 0.35
KMT2A Q03164 4/20 0.34
ATM Q13315 1/20 0.34
TPSAB1 Q15661 1/20 0.34
MEN1 O00255 3/20 0.33
FOLH1 Q04609 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
NAALAD2 Q9Y3Q0 1/20 0.33
SLC1A3 P43003 1/20 0.33
SLC1A2 P43004 1/20 0.33
SLC1A1 P43005 1/20 0.33
SRC P12931 1/20 0.33
MMP2 P08253 1/20 0.32
MMP13 P45452 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6741909 0.91 CTNNB1 (0.41) CYP2A6ADRB3CTNNB1WNT3AMRGPRX4
SCHEMBL6739244 0.89 MMP2 (0.39) CYP2A6ADRB3CTNNB1WNT3AMRGPRX4
SCHEMBL6739240 0.89 MMP2 (0.39) CYP2A6ADRB3CTNNB1WNT3AMRGPRX4
SCHEMBL7056090 0.87 ADRB3 (0.35) CYP2A6ADRB3CTNNB1WNT3AMRGPRX4
SCHEMBL6734434 0.85 LY96 (0.35) CYP2A6ADRB3MRGPRX4MMP2MMP13
SCHEMBL6738949 0.81 MEP1B (0.41) CYP2A6CTNNB1WNT3AMRGPRX4KMT2A
SCHEMBL6738953 0.81 MEP1B (0.41) CYP2A6CTNNB1WNT3AMRGPRX4KMT2A
SCHEMBL7127966 0.81 ATM (0.35) CYP2A6ADRB3CTNNB1WNT3AMRGPRX4
SCHEMBL6740817 0.80 MMP13 (0.43) CYP2A6ADRB3KMT2AMEN1MMP2
SCHEMBL7061656 0.80 MMP2 (0.39) CYP2A6KMT2AMEN1MMP2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-23 US disclosed
EP-1244616-A1 (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SmithKline Beecham plc (GB) 2002-10-02 EP disclosed
WO-2001047874-A1 (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SMITHKLINE BEECHAM P.L.C. (GB) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives CD40, CD22, CD2 CYP2A6 392/4885ADRB3 1104/4885CTNNB1 3925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.